Every material Form 8-K CRH filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
CRH plc disclosed that director Patrick Decker resigned from its Board of Directors effective December 1, 2025, citing unforeseen circumstances. The company said the resignation was not due to any disagreement over its operations, policies or practices, and the Board reduced its size from 13 to 12 members.
Patrick Decker resigned as a Director effective December 1, 2025, citing unforeseen circumstances
The filing states the resignation was not related to any disagreement with the company's operations, policies or practices
Board size reduced from 13 to 12 members following the resignation
CRH reported third-quarter 2025 revenue of $11.1 billion, up 5% from a year earlier, with net income of $1.5 billion (up 9%) and diluted EPS of $2.21 (up 12%). The company reaffirmed its 2025 net income guidance of $3.8 billion to $3.9 billion and raised the midpoint of its adjusted EBITDA guidance to $7.65 billion from $7.6 billion, while also declaring a quarterly dividend of $0.37 per share, up 6%.
Q3 2025 revenue $11.1 billion (up 5%); net income $1.5 billion (up 9%); diluted EPS $2.21 (up 12%)
Adjusted EBITDA $2.7 billion (up 10%); net income margin 13.7%, adjusted EBITDA margin 24.3%
2025 guidance: net income reaffirmed at $3.8 billion to $3.9 billion; adjusted EBITDA midpoint raised to $7.65 billion from $7.6 billion
Quarterly dividend of $0.37 per share, payable Dec. 17, 2025, to holders of record Nov. 21, 2025; net debt rose to $15.0 billion from $10.5 billion at December 31, 2024
CRH's Board increased its size from 12 to 13 members and appointed Patrick Decker as a non-management Director, effective October 1, 2025. Decker is the retired president and CEO of Xylem Inc., and the filing describes his director compensation as following the company's standard non-management director program.
Board size increased from 12 to 13 members; Decker's appointment effective October 1, 2025, decided September 8, 2025
Decker, 60, was president and CEO of Xylem Inc. from March 2014 through December 2023
Decker's RSU award is a pro rata portion of the grant to other non-management directors, covering service until the 2026 Annual General Meeting
Filing states no family relationships or Item 404(a) related-party transactions
CRH reported second-quarter 2025 revenue of $10.2 billion, up 6%, with diluted earnings per share of $1.94, up from $1.88 a year earlier. The company raised its 2025 Adjusted EBITDA and diluted EPS guidance ranges and declared a quarterly dividend of $0.37 per share, up 6%, which matters to shareholders because it reflects higher expected profit and continued cash returns.
Q2 2025 total revenues were $10.2 billion, up 6%; net income was $1.3 billion, up 2%
Diluted EPS was $1.94 versus $1.88 in Q2 2024; Adjusted EBITDA was $2.5 billion, up 9%
2025 Adjusted EBITDA guidance raised to $7.5 billion-$7.7 billion from $7.3 billion-$7.7 billion; diluted EPS guidance raised to $5.49-$5.72 from $5.34-$5.80
Quarterly dividend of $0.37 per share; ex-dividend and record date August 22, 2025; payment date September 24, 2025
CRH's shareholders approved a series of governance changes at the 2025 Annual General Meeting on May 8, 2025, including amendments to the company's Articles effective that day, and re-elected all 12 director nominees. They also approved the CRH plc Equity Incentive Plan, which reserves 15 million ordinary shares and will replace the 2014 Performance Share Plan and other discretionary share plans, with some exceptions.
All 12 director nominees were re-elected; Jim Mintern received 501,900,102 votes for and Richie Boucher received 474,966,274 votes for, with 27,065,642 against.
The Equity Incentive Plan was approved with 483,930,381 votes for and 18,075,734 against.
Shareholders approved amendments to the Articles, including a plurality voting standard for contested director elections and board authority to set its size and director fees.
In an advisory vote, shareholders chose annual 'Say-on-Pay' votes, with 499,105,127 votes for annually.
CRH reported first quarter 2025 results for the period ended March 31, 2025. Total revenues rose 3% to $6.8 billion, but the company posted a net loss of $98 million, compared with net income of $114 million a year earlier, as gains on prior-year divestitures did not recur. Adjusted EBITDA rose 11% to $495 million, and CRH reaffirmed its 2025 guidance, which matters to shareholders because the profit swing and the reaffirmed outlook both bear on expected full-year results.
Total revenues of $6.8 billion, up 3% from $6.5 billion in Q1 2024; net loss of $98 million versus net income of $114 million a year earlier.
Diluted loss per share of ($0.15), compared with diluted earnings per share of $0.16 in Q1 2024.
Adjusted EBITDA of $495 million, up 11%; Adjusted EBITDA margin of 7.3%, up from 6.8%.
2025 guidance reaffirmed: net income of $3.7 billion to $4.1 billion and Adjusted EBITDA of $7.3 billion to $7.7 billion. A $0.37 quarterly dividend was declared and a new $0.3 billion buyback tranche is to be completed no later than August
CRH announced that Nancy Buese, former CFO of Baker Hughes and Newmont, will become its Chief Financial Officer effective May 12, 2025, replacing interim CFO Alan Connolly, who returns to his prior role as Director of Strategic Finance on May 11, 2025. The filing sets out her pay package, including a $1,000,000 base salary and a target equity award of $4,000,000 for 2025, which shareholders may track in future disclosures.
Nancy Buese appointed CFO effective May 12, 2025; Alan Connolly serves as interim CFO until May 11, 2025
Base salary of $1,000,000, target bonus of 110% of base salary, and target 2025 equity award with grant date fair value of $4,000,000
One-time cash bonus of $1,000,000 and one-time RSU grant of $2,000,000 vesting 50% in 2026 and 50% in 2027
Employment agreement dated April 11, 2025; full agreement to be filed with the Form 10-Q for the quarter ended March 31, 2025
CRH reported fourth-quarter and full-year 2024 results on February 26, 2025. Full-year revenue was $35.6 billion, up 2%, while net income rose 15% to $3.5 billion and basic EPS rose 16% to $5.06. The company also guided 2025 net income to $3.7 billion to $4.1 billion and adjusted EBITDA to $7.3 billion to $7.7 billion, and it raised the quarterly dividend to $0.37.
FY 2024 total revenues $35.6 billion, up 2%; net income $3.5 billion, up 15%; adjusted EBITDA $6.9 billion, up 12%
FY 2024 basic EPS $5.06, up 16%; Q4 2024 basic EPS $1.03, up 4%
2025 guidance: net income $3.7 billion to $4.1 billion; adjusted EBITDA $7.3 billion to $7.7 billion; diluted EPS $5.34 to $5.80
Quarterly dividend increased to $0.37 per share; new $0.3 billion share buyback tranche to be completed by May 2, 2025; net debt rose to $10.5 billion
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CRH filing is on SEC EDGAR ↗. 8-K briefs of other companies →